Neovascular Age-related Macular Degeneration
Conditions
Keywords
Wet Age-related Macular Degeneration
Brief summary
In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with wAMD.
Detailed description
Age-related macular degeneration (AMD) is a major cause of blindness and visual impairment in older adults. The wet form of AMD, also called neovascular AMD (nAMD) usually causes faster vision loss than the dry form. The most common current treatments of nAMD are products that inhibit vascular endothelial growth factor (VEGF) (including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron) and are delivered by intravitreal injections at 4 to 16 week intervals and continued indefinitely. This Open-label, Dose-escalation Phase I/IIa Study is designed to evaluate the safety and efficacy of EXG102-031 intraocular Injection in participants with wet(Neovascular) Age-related Macular Degeneration（wAMD）.
Interventions
BIOLOGICALEXG102-031
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
Sponsors
Hangzhou Jiayin Biotech Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, age ≥ 50 years of age; 2. Diagnosis of wAMD and current active lesion in the study eye at Screening; 3. An ETDRS BCVA letter scores between 73 and 9 letters in the study eye; 4. Response to anti-VEGF treatment within 6 months prior to screening or at the time of screening introduction; 5. The study eye must be a Intraocular lens eye(post-cataract surgery status) and be at least 1 month post IOL implantation at enrollment; 6. Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening.
Exclusion criteria
1. Presence of any ocular disease or history of disease in the study eye other than wAMD that may affect central visual acuity and/or macular detection; 2. Presence in the study eye of CNV or macular pathology pathography due to causes other than wAMD; 3. The study eye has severe and irreversible retinal structural damage involving the fovea (such as retinal pigment epithelial (RPE) atrophy, retinal fibrosis, laser scars, dense hard exudation); Or other retinal damage in the target eye that, in the opinion of the investigator, may impede visual improvement after resolution of macular edema ; 4. Subretinal hemorrhage accumulating the central fovea of the study eye, with an area of hemorrhage ≥ 4 optic disc diameters; 5. Presence of advanced glaucoma or uncontrolled ocular hypertension in the study eye; 6. Prior receipt of any ocular or systemic gene therapy agent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) | 24 weeks following EXG102-031 administration | incidence of ocular and non-ocular AEs and SAEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) | 52 weeks following EXG102-031 administration | incidence of ocular and non-ocular AEs and SAEs |
| Change From Baseline in BCVA (Best Corrected Visual Acuity) | 52 weeks following EXG102-031 administration | Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. |
| Change From Baseline in CRT (Central Retinal Thickness) | 52 weeks following EXG102-031 administration | Retinal fluid status of the study eye was evaluated using spectral domain OCT (Optical Coherence Tomography). A decrease in value indicates a decrease in fluid |
| Supplemental Injections (Annualized Rate of Supplemental Injections) | 52 weeks following EXG102-031 administration | The number of supplemental anti-VEGF injections given after EXG102-031 was administered. |
Countries
China
Contacts
Primary ContactSara Yang
Outcome results
None listed